Annual EBITDA
-$132.25 M
+$26.16 M+16.51%
December 31, 2024
Summary
- As of March 10, 2025, ALXO annual EBITDA is -$132.25 million, with the most recent change of +$26.16 million (+16.51%) on December 31, 2024.
- During the last 3 years, ALXO annual EBITDA has fallen by -$48.83 million (-58.53%).
- ALXO annual EBITDA is now -897.73% below its all-time high of -$13.26 million, reached on December 31, 2018.
Performance
ALXO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$28.52 M
+$1.51 M+5.04%
December 31, 2024
Summary
- As of March 10, 2025, ALXO quarterly EBITDA is -$28.52 million, with the most recent change of +$1.51 million (+5.04%) on December 31, 2024.
- Over the past year, ALXO quarterly EBITDA has stayed the same.
- ALXO quarterly EBITDA is now -875.11% below its all-time high of -$2.92 million, reached on September 30, 2019.
Performance
ALXO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$132.25 M
+$16.33 M+10.99%
December 31, 2024
Summary
- As of March 10, 2025, ALXO TTM EBITDA is -$132.25 million, with the most recent change of +$16.33 million (+10.99%) on December 31, 2024.
- Over the past year, ALXO TTM EBITDA has stayed the same.
- ALXO TTM EBITDA is now -3100.61% below its all-time high of -$4.13 million, reached on March 31, 2019.
Performance
ALXO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALXO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.5% | 0.0% | 0.0% |
| 3 y3 years | -58.5% | -16.6% | -41.2% |
| 5 y5 years | -605.0% | -100.8% | -151.7% |
ALXO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -58.5% | +16.5% | -16.6% | +43.4% | -58.5% | +21.7% |
| 5 y | 5-year | -605.0% | +16.5% | -456.9% | +43.4% | -605.0% | +21.7% |
| alltime | all time | -897.7% | +16.5% | -875.1% | +43.4% | -3100.6% | +21.7% |
ALX Oncology Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$132.25 M(-16.5%) | -$28.52 M(-5.0%) | -$132.25 M(-11.0%) |
| Sep 2024 | - | -$30.04 M(-22.5%) | -$148.58 M(-12.0%) |
| Jun 2024 | - | -$38.75 M(+10.9%) | -$168.93 M(+3.2%) |
| Mar 2024 | - | -$34.94 M(-22.1%) | -$163.76 M(+3.4%) |
| Dec 2023 | -$158.40 M(+29.0%) | -$44.85 M(-11.0%) | -$158.40 M(+10.1%) |
| Sep 2023 | - | -$50.39 M(+50.1%) | -$143.86 M(+11.8%) |
| Jun 2023 | - | -$33.58 M(+13.5%) | -$128.70 M(+0.6%) |
| Mar 2023 | - | -$29.58 M(-2.4%) | -$127.95 M(+4.2%) |
| Dec 2022 | -$122.84 M(+47.3%) | -$30.31 M(-14.0%) | -$122.84 M(+1.6%) |
| Sep 2022 | - | -$35.22 M(+7.3%) | -$120.88 M(+9.7%) |
| Jun 2022 | - | -$32.83 M(+34.2%) | -$110.23 M(+17.7%) |
| Mar 2022 | - | -$24.47 M(-13.7%) | -$93.69 M(+12.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$83.42 M(+91.9%) | -$28.35 M(+15.4%) | -$83.42 M(+15.1%) |
| Sep 2021 | - | -$24.57 M(+50.8%) | -$72.48 M(+25.3%) |
| Jun 2021 | - | -$16.29 M(+14.7%) | -$57.82 M(+10.0%) |
| Mar 2021 | - | -$14.20 M(-18.4%) | -$52.54 M(+20.9%) |
| Dec 2020 | -$43.46 M(+131.7%) | -$17.41 M(+75.6%) | -$43.46 M(+29.1%) |
| Sep 2020 | - | -$9.91 M(-10.0%) | -$33.67 M(+26.2%) |
| Jun 2020 | - | -$11.01 M(+115.0%) | -$26.68 M(+35.1%) |
| Mar 2020 | - | -$5.12 M(-32.8%) | -$19.75 M(+5.3%) |
| Dec 2019 | -$18.76 M(+41.5%) | -$7.62 M(+160.6%) | -$18.76 M(+68.4%) |
| Sep 2019 | - | -$2.92 M(-28.3%) | -$11.14 M(+35.6%) |
| Jun 2019 | - | -$4.08 M(-1.3%) | -$8.21 M(+98.7%) |
| Mar 2019 | - | -$4.13 M | -$4.13 M |
| Dec 2018 | -$13.26 M | - | - |
FAQ
- What is ALX Oncology Holdings annual EBITDA?
- What is the all time high annual EBITDA for ALX Oncology Holdings?
- What is ALX Oncology Holdings annual EBITDA year-on-year change?
- What is ALX Oncology Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for ALX Oncology Holdings?
- What is ALX Oncology Holdings quarterly EBITDA year-on-year change?
- What is ALX Oncology Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for ALX Oncology Holdings?
- What is ALX Oncology Holdings TTM EBITDA year-on-year change?
What is ALX Oncology Holdings annual EBITDA?
The current annual EBITDA of ALXO is -$132.25 M
What is the all time high annual EBITDA for ALX Oncology Holdings?
ALX Oncology Holdings all-time high annual EBITDA is -$13.26 M
What is ALX Oncology Holdings annual EBITDA year-on-year change?
Over the past year, ALXO annual EBITDA has changed by +$26.16 M (+16.51%)
What is ALX Oncology Holdings quarterly EBITDA?
The current quarterly EBITDA of ALXO is -$28.52 M
What is the all time high quarterly EBITDA for ALX Oncology Holdings?
ALX Oncology Holdings all-time high quarterly EBITDA is -$2.92 M
What is ALX Oncology Holdings quarterly EBITDA year-on-year change?
Over the past year, ALXO quarterly EBITDA has changed by $0.00 (0.00%)
What is ALX Oncology Holdings TTM EBITDA?
The current TTM EBITDA of ALXO is -$132.25 M
What is the all time high TTM EBITDA for ALX Oncology Holdings?
ALX Oncology Holdings all-time high TTM EBITDA is -$4.13 M
What is ALX Oncology Holdings TTM EBITDA year-on-year change?
Over the past year, ALXO TTM EBITDA has changed by $0.00 (0.00%)